The Evaluation of Spells
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Progestin-Only Systemic Hormone Therapy for Menopausal Hot Flashes
EDITORIAL Progestin-only systemic hormone therapy for menopausal hot flashes Clinicians treating postmenopausal hot flashes often recommend “systemic estrogen treatment.” However, progestin-only therapy also can effectively treat hot flashes and is an option for women with a contraindication to estrogen therapy. Robert L. Barbieri, MD Editor in Chief, OBG MANAGEMENT Chair, Obstetrics and Gynecology Brigham and Women’s Hospital Boston, Massachusetts Kate Macy Ladd Professor of Obstetrics, Gynecology and Reproductive Biology Harvard Medical School he field of menopause medi- women. In one study, 133 postmeno- in postmenopausal women with cine is dominated by studies pausal women with an average age an American Heart Association risk T documenting the effective- of 55 years and approximately 3 years score greater than 10% over 10 years.3 ness of systemic estrogen or estro- from their last menstrual period were Additional contraindications to sys- gen-progestin hormone therapy for randomly assigned to 12 weeks of temic estrogen include women with the treatment of hot flashes caused treatment with placebo or micronized cardiac disease who have a throm- by hypoestrogenism. The effective- progesterone 300 mg daily taken at bophilia, such as the Factor V Leiden ness of progestin-only systemic bedtime.1 Mean serum progesterone mutation.4 hormone therapy for the treatment levels were 0.28 ng/mL (0.89 nM) and For women who are at high risk of hot flashes is much less studied 27 ng/mL (86 nM) in the women taking for estrogen-induced cardiovascu- and seldom is utilized in clinical placebo and micronized progesterone, lar events, micronized progesterone practice. -
Fast Facts About Social Phobia
PLEASE TEAR OUT AND PHOTOCOPY FOR YOUR PATIENTS!! PATIENTS AS PARTNERS Brought to you by The South African Depression and Anxiety Group Tel: +27 11 783 1474 Fax: +27 11 884 7074 E-mail: [email protected] website: www.anxiety.org.za Fast facts about social phobia • Social Phobia affects an estimated one in ten people. It affects people of all races and social classes. • It is estimated that fewer than 25% of people with Social Phobia receive adequate treatment. • The onset of Social Phobia is typically during adolescence, but it may occur in childhood, prior to the age of ten. Approximately 40% of social phobias appear before the age of ten, and 95% before the age of twenty. • Social Phobia is characterised by an underlying fear of scrutiny by people in social situations. It is also associated with fear of performance situations in which embarrassment may occur. • Social Phobia is not shyness. A person with social phobia who finds it unbearable to sign a cheque in public, might be quite extroverted in other contexts. • People with social phobia will avoid social or occupational situations where their particular anxiety might be provoked for eg urinating in a public restroom, or giving a speech. • Common fears include: being introduced to others, meeting people in authority, using the telephone, eating in restaurants or writing in front of others. • When faced with a feared situation, people may have symptoms of panic, e.g. heart palpitations, trembling, sweating, hot and cold flushes and blushing. • 45% of people with social phobia will develop agoraphobia, where their fear of having a panic attack in a social setting will lead them to avoiding social settings altogether. -
6 Ways Your Brain Transforms During Menopause
6 Ways Your Brain Transforms During Menopause By Aviva Patz Movies and TV shows have gotten a lot of laughs out of menopause, with its dramatic hot flashes and night sweats. But the midlife transition out of our reproductive years—marked by yo-yoing of hormones, mostly estrogen—is a serious quality-of-life issue for many women, and as we're now learning, may leave permanent marks on our health. "There is a critical window hypothesis in that what is done to treat the symptoms and risk factors during perimenopause predicts future health and symptoms," explains Diana Bitner, MD, assistant professor at Michigan State University College of Human Medicine and author of I Want to Age Like That: Healthy Aging Through Midlife and Menopause. "If women act on the mood changes in perimenopause and get healthy and take estrogen, the symptoms are much better immediately and also lifelong." (Going through menopause and your hormones are out of whack? Then check out The Hormone Reset Diet to balance your hormones and lose weight.) For many decades, the mantra has been that the only true menopausal symptoms are hot flashes and vaginal dryness. Certainly they're the easiest signs to spot! But we have estrogen receptors throughout the brain and body, so when estrogen levels change, we experience the repercussions all over—especially when it comes to how we think and feel. Two large studies, including one of the nation's longest longitudinal investigations, have revealed that there's a lot going on in the brain during this transition. "Before it was hard to tease out: How much of this is due to the ovaries aging and how much is due to the whole body aging?" says Pauline Maki, PhD, professor of psychiatry and psychology at the University of Illinois at Chicago and Immediate Past President of the North American Menopause Society (NAMS). -
Panic Disorder
Panic Disorder The Anxiety Disorders Association of America (ADAA) is a national 501 (c)3 nonprofit organization whose My heart’s pounding, mission is to promote the prevention, treatment and cure of anxiety disorders and to improve the lives of all it’s hard to breathe. people who suffer from them. Help ADAA help others. Donate now at www.adaa.org. “I feel like I’m going to go crazy or die. For information visit www.adaa.org or contact I have to get out Anxiety Disorders Association of America 8730 Georgia Ave., Ste. 600 of here NOW. Silver Spring, MD 20910 Phone: 240-485-1001 ” Anxiety Disorders Association of America What is Panic Disorder? About Anxiety Disorders We’ve all experienced that gut-wrenching fear when suddenly faced with a threatening or dangerous situation. Crossing the street as a car shoots out of nowhere, losing a child in Anxiety is a normal part of living. It’s the body’s way of telling the playground or hearing someone scream fire in a crowded us something isn’t right. It keeps us from harm’s way and theater. The momentary panic sends chills down our spines, prepares us to act quickly in the face of danger. However, for causes our hearts to beat wildly, our stomachs to knot and some people, anxiety is persistent, irrational and overwhelming. our minds to fill with terror. When the danger passes, so do It may get in the way of day-to-day activities and even make the symptoms. We’re relieved that the dreaded terror didn’t them impossible. -
Abnormal Noradrenergic Function in Posttraumatic Stress Disorder
Original Article Abnormal Noradrenergic Function in Posttraumatic Stress Disorder Steven M. Southwick, MD; John H. Krystal, MD; C. Andrew Morgan, MD; David Johnson, PhD; Linda M. Nagy, MD; Andreas Nicolaou, PhD; George R. Heninger, MD; Dennis S. Charney, MD • To evaluate possible abnormal noradrenergic neuronal of stress. The effects of stress on brain noradrenergic func regulation in patients with posttraumatic stress disorder tion have been particularly well studied. For example, (PTSD), the behavioral, biochemical, and cardiovascular stress, especially uncontrollable stress, produces an ele effects of intravenous yohimbine hydrochloride (0.4 mg/kg) vated sense of fear and anxiety and causes regional were determined in 18 healthy male subjects and 20 male increases in norepinephrine turnover in the locus ceruleus patients with PTSD. A subgroup of patients with PTSD were (LC), limbic regions (hypothalamus, hippocampus, and observed to experience yohimbine-induced panic attacks amygdala), and cerebral cortex.3,4 In addition, a series of (70% [14/20]) and flashbacks (40% [8/20]), and they had investigations have shown that uncontrollable stress re larger yohimbine-induced increases in plasma 3-methoxy sults in an increased responsiveness of LC neurons to ex 4-hydroxyphenylglycol levels, sitting systolic blood pres citatory stimulation that is associated with a reduction in 5,6 sure, and heart rate than those in healthy subjects. In addi a2-adrenergic autoreceptor sensitivity. tion, in the patients with PTSD, yohimbine induced Recent clinical investigations suggest that a subgroup of significant increases in core PTSD symptoms, such as intru patients with chronic PTSD may exhibit abnormalities in sive traumatic thoughts, emotional numbing, and grief. -
What Is a Panic Attack Disorder Within a Given Year
11/6/2014 Top 3 Things You Should Know About Panic Attacks From: Tramaine Stevenson, Director of Program Development and Operations, National Council Date sent 11/05/2014 02:11:49 pm Subject: Top 3 Things You Should Know About Panic Attacks If you have difficulty viewing this message please click here. Interested in becoming a Mental Health First Aid instructor? Check out our Mental Health First Aider eNews recently announced National Council- hosted instructor trainings in California, In this week's issue, we discuss the top 3 things you should know South Carolina, Tennessee, New about panic attacks: what they are, what they look like, and how Mexico, and Texas. you can help using your Mental Health First Aid skills. More than 1 in 5 people will experience a panic attack in their lifetime. 2.7% of adults will develop a panic What is a Panic Attack disorder within a given year. A panic attack is a sudden onset of intense anxiety, fear, or terror that often occurs for no clear reason. Panic attacks can occur at any time—even in your sleep. Panic attacks peak around 10 minutes, but the physical symptoms can extend for a longer period of time. Panic disorder is when a person experiences recurring panic attacks and is persistently http://echo4.bluehornet.com/hostedemail/email.htm?CID=28367546178&ch=9E17608366076582BB3B29A03EE35827&h=cc4156c7bda4f2955eef9d28160531fa&… 1/4 11/6/2014 Top 3 Things You Should Know About Panic Attacks worried—for at least 1 month—about possible future panic attacks and the consequences of panic attacks. Some individuals with panic disorder go on to develop agoraphobia: avoiding places due to the fear of having a panic attack. -
Duloxetine and Escitalopram for Hot Flushes: Efficacy and Compliance in Breast Cancer Survivors
Original Article Duloxetine and escitalopram for hot flushes: efficacy and compliance in breast cancer survivors N. BIGLIA, MD, PHD, Gynaecology and Obstetrics Unit, Umberto I Hospital, Department of Surgical Sciences, University of Turin, Turin, V.E. BOUNOUS, MD, Gynaecology and Obstetrics Unit, Umberto I Hospital, Department of Surgical Sciences, University of Turin, Turin, T. SUSINI, MD, PHD, Breast Unit Department of Health Science, OB & GYN Section, AOU Careggi, School of Medicine, University of Florence, Florence, S. PECCHIO, MD, Gynaecology and Obstetrics Unit, Umberto I Hospital, Department of Surgical Sciences, University of Turin, Turin, L.G. SGRO, MD, PHD, Gynaecology and Obstetrics Unit, Umberto I Hospital, Department of Surgical Sciences, University of Turin, Turin, V. TUNINETTI, Gynaecology and Obstetrics Unit, Umberto I Hospital, Department of Surgical Sciences, University of Turin, Turin, & R. TORTA, MD, PHD, Psycho-Oncology Unit, Department of Neurosciences, University of Turin, Turin, Italy BIGLIA N., BOUNOUS V.E., SUSINI T., PECCHIO S., SGRO L.G., TUNINETTI V. & TORTA R. (2016) Euro- pean Journal of Cancer Care Duloxetine and escitalopram for hot flushes: efficacy and compliance in breast cancer survivors Selective serotonin reuptake inhibitors (SSRI) and serotonin–norepinephrine reuptake inhibitors (SNRI) might be an effective treatment for hot flushes (HFs) in breast cancer survivors (BCSs). This study aims to compare the efficacy and tolerability of duloxetine (SNRI) versus escitalopram (SSRI) in reducing frequency and severity of HFs in BCSs and to assess the effect on depression. Thirty-four symptomatic BCSs with emotional impairment received randomly duloxetine 60 mg daily or escitalopram 20 mg daily for 12 weeks. Patients were asked to record in a diary HF frequency and severity at baseline and after 4 and 12 weeks of treatment. -
[Product Monograph Template
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrORILISSA® elagolix (as elagolix sodium) tablets 150 mg and 200 mg Gonadotropin releasing hormone (GnRH) receptor antagonist Date of Preparation: October 4, 2018 AbbVie Corporation Date of Revision: 8401 Trans-Canada Highway March 3, 2020 St-Laurent, Qc H4S 1Z1 Submission Control No: 233793 ORILISSA Product Monograph Page 1 of 40 Date of Revision: March 3, 2020 and Control No. 233793 RECENT MAJOR LABEL CHANGES Not applicable. TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ............................................................... 4 1. INDICATIONS ................................................................................................................ 4 1.1. Pediatrics (< 18 years of age): .................................................................................. 4 1.2. Geriatrics (> 65 years of age): .................................................................................. 4 2. CONTRAINDICATIONS ................................................................................................. 4 3. DOSAGE AND ADMINISTRATION ................................................................................ 5 3.1. Dosing Considerations ............................................................................................. 5 3.2. Recommended Dose and Dosage Adjustment ......................................................... 5 3.3. Administration ......................................................................................................... -
EMDR Therapy Protocol for Panic Disorders with Or Without Agoraphobia 53
PANIC DISORDER AND AGORAPHOBIA EMDR Therapy Protocol for Panic Disorders 2 With or Without Agoraphobia Ferdinand Horst and Ad de Jongh Introduction Panic disorder, as stated in the Diagnostic and Statistical Manual of Mental Disorders, fi fth edition (DSM-5; American Psychiatric Association, 2013) is characterized by recurrent and unexpected panic attacks and by hyperarousal symptoms like palpitations, pounding heart, chest pain, sweating, trembling, or shaking. These symptoms can be experienced as cata- strophic (“I am dying”) and mostly have a strong impact on daily life. When panic disorder is accompanied by severe avoidance of places or situations from which escape might be diffi cult or embarrassing, it is specifi ed as “panic disorder with agoraphobia” (American Psychiatric Association, 2013). EMDR Therapy and Panic Disorder With or Without Agoraphobia Despite the well-examined effectiveness of Eye Movement Desensitization and Reprocessing (EMDR) Therapy in the treatment of posttraumatic stress disorder (PTSD), the applicability of EMDR Therapy for other anxiety disorders, like panic disorders with or without agora- phobia (PDA or Pathological Demand Avoidance), has hardly been examined (de Jongh & ten Broeke, 2009). From a theoretical perspective, there are several reasons why EMDR Therapy could be useful in the treatment of panic disorder: 1. The occurrence of panic attacks is likely to be totally unexpected; therefore, they are often experienced as distressing, causing a subjective response of fear or help- lessness. Accordingly, panic attacks can be viewed as life-threatening experiences (McNally & Lukach, 1992; van Hagenaars, van Minnen, & Hoogduin, 2009). 2. Panic memories in panic disorder resemble traumatic memories in PTSD in the sense that the person painfully reexperiences the traumatic incident in the form of recurrent and distressing recollections of the event, including intrusive images and fl ashbacks (van Hagenaars et al., 2009). -
Non-Hormonal Strategies for Managing Menopausal Symptoms in Cancer Survivors: an Update
Non-hormonal strategies for managing menopausal symptoms in cancer survivors: an update Nicoletta Biglia1, Valentina E Bounous1, Francesco De Seta2, Stefano Lello3, Rossella E Nappi4 and Anna Maria Paoletti5 1Division of Gynecology and Obstetrics, Department of Surgical Sciences, School of Medicine, University of Torino, Largo Turati 62, 10128 Torino, Italy 2Institute for Maternal and Child Health-IRCCS ‘Burlo Garofolo’, University of Trieste, via dell’Istria 65/1, 34137 Trieste, Italy 3Department of Woman and Child Health, Policlinico Gemelli Foundation, Largo Gemelli 1, 00168 Rome, Italy 4Research Center for Reproductive Medicine, Gynecological Endocrinology and Menopause, IRCCS S Matteo Foundation, Department of Clinical, Surgical, Diagnostic and Paediatric Sciences, University of Pavia, Viale Camillo Golgi 19, 27100 Pavia, Italy 5 Department of Obstetrics and Gynecology, Department of Surgical Sciences, University of Cagliari, University Hospital of Cagliari, SS 554 km 4,500, 09042 Monserrato, Italy Abstract Vasomotor symptoms, particularly hot flushes (HFs), are the most frequently reported symptom by menopausal women. In particular, for young women diagnosed with breast cancer, who experience premature ovarian failure due to cancer treatments, severe HFs are an unsolved problem that strongly impacts on quality of life. The optimal manage- ment of HFs requires a personalised approach to identify the treatment with the best Review benefit/risk profile for each woman. Hormonal replacement therapy (HRT) is effective in managing HFs but it is contraindicated in women with previous hormone-dependent cancer. Moreover, many healthy women are reluctant to take HRT and prefer to manage symptoms with non-hormonal strategies. In this narrative review, we provide an update on the current available non-oestrogenic strategies for HFs management for women who cannot, or do not wish to, take oestrogens. -
Panic Attacks
Information from your Patient Aligned Care Team Panic Attacks What is a panic attack? You may have had a panic attack if you experienced four or more of the symptoms listed below coming on abruptly and peaking in about 10 minutes. Panic Symptoms . Pounding heart . Feeling dizzy, unsteady, lightheaded, or faint . Sweating . Feelings of unreality or being detached from yourself . Trembling or shaking . Fear of losing control or going crazy . Shortness of breath . Fear of dying . Feeling of choking . Numbness or tingling . Chest pain . Chills or hot flashes . Nausea or abdominal distress Panic attacks are sometimes accompanied by avoidance of certain places or situations. These are often situations that would be difficult to escape from or in which help might not be available. Examples might include crowded shopping malls, public transportation, restaurants, or driving. Why do panic attacks occur? Panic attacks are the body’s alarm system gone awry. All of us have a built-in alarm system, powered by adrenaline, which increases our heart rate, breathing, and blood flow in response to danger. Ordinarily, this ‘danger response system’ works well. In some people, however, the response is either out of proportion to whatever stress is going on, or may come out of the blue without any stress at all. For example, if you are walking in the woods and see a bear coming your way, a variety of changes occur in your body to prepare you to either fight the danger or flee from the situation. Your heart rate will increase to get more blood flow around your body, your breathing rate will quicken so that more oxygen is available, and your muscles will tighten in order to be ready to fight or run. -
Medical Evaluation of VHL-Related Adrenal Tumors
Medical Evaluation of VHL-Related Adrenal Tumors Colleen Majewski, MD University of Chicago Section of Endocrinology, Diabetes, and Metabolism October 17, 2015 Outline • How does VHL manifest in the adrenal glands? • How are adrenal gland tumors diagnosed? • How do endocrinologists detect and manage these tumors? VHL: A Multisystemic Cancer Syndrome Adrenal Gland Adrenaline Pheochromocytoma • Adrenaline producing tumor in the adrenal gland • Benign or malignant • Type 1 VHL • Lower risk of developing a pheochromocytoma • Type 2 VHL • High risk of developing a pheochromocytoma Paraganglioma • An adrenaline-producing tumor that is outside of the adrenal gland • Arise near ganglia (bundles of nerves) along blood vessels: • Parasympathetic paraganglioma: • Along nerves in the neck and base of the head • Most do not produce adrenaline • Sympathetic paraganglioma: • Along nerves in the chest, abdomen, and pelvis • Most do produce adrenaline • Rare: Dopamine low blood pressure Paraganglioma Do All Pheochromocytomas or Paragangliomas Produce Excess Adrenaline? No . If they are detected early, less likely to produce adrenaline . Paragangliomas in the head and neck rarely produce adarenaline . Paragangliomas in the chest and abdomen often produce adrenaline . About two-thirds of pheochromocytomas/paragangliomas produce excess adrenaline in patients with VHL Symptoms of Pheochromocytoma and Paraganglioma • “Feels like a panic attack” • Headache • Sweating • Fast heart rate, palpitations • High blood pressure • May have no symptoms Adrenaline Fast